Double maintains 3 strategies that include SUPN - Supernus Pharmaceuticals, Inc.
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
AUDC | -0.01% | $270.68M | -8.71% | 3.81% |
APPN | -0.04% | $2.22B | +11.79% | 0.00% |
DAO | -0.14% | $272.46M | +139.29% | 0.00% |
MNOV | -0.14% | $61.80M | -3.82% | 0.00% |
EQX | 0.17% | $2.89B | +18.73% | 0.00% |
TCOM | -0.20% | $39.63B | +21.46% | 0.52% |
TME | -0.21% | $12.73B | +26.74% | 0.98% |
CEG | -0.23% | $95.81B | +38.70% | 0.48% |
IMNN | -0.23% | $19.82M | +5.61% | 0.00% |
RLX | -0.24% | $2.01B | +22.78% | 0.46% |
AGL | 0.29% | $869.30M | -68.84% | 0.00% |
CRMD | -0.30% | $945.48M | +221.94% | 0.00% |
MSIF | -0.31% | $820.39M | +45.09% | 6.03% |
EH | 0.31% | $853.01M | +12.27% | 0.00% |
TLN | -0.32% | $13.01B | +144.97% | 0.00% |
GPCR | 0.35% | $1.21B | -55.87% | 0.00% |
NOAH | 0.36% | $828.17M | +31.76% | 8.56% |
OXBR | -0.36% | $11.91M | -33.05% | 0.00% |
MDGL | 0.37% | $6.21B | +1.30% | 0.00% |
DXCM | -0.37% | $32.09B | -29.84% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
EDIT | -21.87% | $179.15M | -57.54% | 0.00% |
FMTO | -14.92% | $4.80K | -99.93% | 0.00% |
MSB | -13.87% | $312.65M | +38.14% | 30.00% |
COMP | -12.26% | $3.17B | +66.30% | 0.00% |
EYE | -11.38% | $1.77B | +72.27% | 0.00% |
LITB | -11.29% | $22.07M | -76.50% | 0.00% |
CNC | -10.69% | $27.32B | -17.29% | 0.00% |
SMCI | -10.49% | $25.73B | -53.14% | 0.00% |
CREG | -9.42% | $7.30M | -69.80% | 0.00% |
K | -8.52% | $27.83B | +36.45% | 2.85% |
CELH | -7.80% | $11.38B | -30.21% | 0.00% |
SOHU | -7.78% | $329.52M | -16.02% | 0.00% |
SGC | -6.96% | $158.71M | -47.79% | 5.67% |
LPTH | -6.73% | $126.12M | +140.98% | 0.00% |
AEM | -6.47% | $62.64B | +91.78% | 1.28% |
GFI | -6.42% | $21.74B | +73.25% | 2.27% |
PHYS | -6.30% | - | - | 0.00% |
CYD | -6.19% | $811.15M | +138.90% | 1.72% |
NEXT | -6.00% | $2.19B | +10.10% | 0.00% |
AVNW | -5.93% | $288.45M | -22.91% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
RVLV | 47.50% | $1.46B | +29.14% | 0.00% |
PRG | 44.76% | $1.15B | -20.00% | 1.73% |
INGN | 44.06% | $174.23M | -15.24% | 0.00% |
RYAM | 43.41% | $259.09M | -33.45% | 0.00% |
HHH | 43.28% | $3.49B | +11.23% | 0.00% |
GNW | 40.48% | $2.83B | +13.81% | 0.00% |
INSP | 39.21% | $3.75B | -21.63% | 0.00% |
SAH | 39.12% | $2.61B | +34.69% | 1.76% |
HOPE | 38.95% | $1.28B | -1.47% | 5.53% |
BANF | 38.31% | $3.92B | +40.69% | 1.53% |
HONE | 38.14% | $472.71M | +5.58% | 2.99% |
WSFS | 37.79% | $2.89B | +12.93% | 1.21% |
PGC | 37.76% | $470.36M | +23.52% | 0.75% |
BRKL | 37.74% | $892.83M | +21.90% | 5.37% |
ASB | 37.62% | $3.75B | +11.15% | 3.99% |
HWC | 37.61% | $4.55B | +19.05% | 3.17% |
BMBL | 37.55% | $540.21M | -48.12% | 0.00% |
NWBI | 37.49% | $1.54B | +10.86% | 6.63% |
KMT | 37.43% | $1.69B | -6.39% | 3.61% |
FHB | 37.35% | $2.90B | +14.91% | 4.49% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
PALL | -0.04% | $457.89M | 0.6% |
BILZ | 0.07% | $840.57M | 0.14% |
LMBS | 0.09% | $5.05B | 0.64% |
MTBA | 0.10% | $1.47B | 0.17% |
KBA | 0.11% | $171.69M | 0.56% |
VMBS | 0.11% | $14.31B | 0.03% |
IBMO | 0.12% | $522.31M | 0.18% |
FXE | -0.16% | $564.66M | 0.4% |
FEMB | 0.19% | $161.45M | 0.85% |
GCOR | 0.21% | $567.54M | 0.08% |
EDV | -0.24% | $3.38B | 0.05% |
SCHP | 0.25% | $12.74B | 0.03% |
VCRB | -0.26% | $3.02B | 0.1% |
HYDR | -0.26% | $32.57M | 0.5% |
USCI | 0.30% | $242.50M | 1.07% |
TLTW | -0.33% | $1.10B | 0.35% |
JMBS | -0.37% | $5.48B | 0.22% |
JSI | -0.39% | $834.92M | 0.49% |
AGG | -0.40% | $126.19B | 0.03% |
CPER | 0.42% | $198.71M | 0.97% |
Yahoo
H.C. Wainwright analyst Douglas Tsao says that while a takeover of Sage Therapeutics (SAGE) comes as no surprise, but a deal with Supernus (SUPN) is unexpected, and “leaves open the door for additional competition.” The merger agreement includes a “modest” breakup fee of just $22.4M payable to Supernus in the event Sage accepts a superior offer, the analyst tells investors in a research note. The firm believes the “relatively modest breakup fee” would not dissuade Biogen (BIIB) from pursuing a b
Yahoo
SUPN inks deal to acquire Sage Therapeutics for up to $795 million, securing rights to depression drug Zurzuvae.
Yahoo
Sage Therapeutics (SAGE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Yahoo
Stock market futures are up slightly. Enthusiasm has been tempered by geopolitical risks and uncertainty ahead of Wednesday’s Federal Reserve decision. The Fed is widely expected to hold rates steady, but investors are laser-focused on Chair Powell’s language regarding potential rate cuts later this year. Currently, markets are pricing in a roughly 56% chance of a quarter-point cut by September. In the background, rising tensions between Israel and Iran continue to cast a long shadow. Oil prices
Finnhub
NEW YORK, June 16, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Sage Therapeutics, Inc. and its board of directors concerning the proposed acquisition...
Finnhub
The following bids, mergers,acquisitions and disposals were reported by 1330 GMT on Monday: ** Justin Sun's crypto platform, Tron, has reached a dealwith Nasdaq-listed...
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
RWJ | 38.44% | $1.47B | 0.39% |
XSLV | 38.36% | $279.52M | 0.25% |
SLYV | 37.68% | $3.59B | 0.15% |
VIOV | 37.67% | $1.24B | 0.1% |
IJS | 37.65% | $5.97B | 0.18% |
EES | 37.62% | $572.75M | 0.38% |
RZV | 37.47% | $200.29M | 0.35% |
SMDV | 36.87% | $642.20M | 0.4% |
BSVO | 36.67% | $1.41B | 0.47% |
SPSM | 36.66% | $10.98B | 0.03% |
DES | 36.63% | $1.82B | 0.38% |
XSVM | 36.63% | $553.48M | 0.37% |
IWN | 36.63% | $10.67B | 0.24% |
SMMV | 36.48% | $307.70M | 0.2% |
DFAT | 36.41% | $10.35B | 0.28% |
XPH | 36.32% | $151.38M | 0.35% |
REGL | 36.13% | $1.76B | 0.4% |
FYX | 36.13% | $799.62M | 0.6% |
KBE | 36.08% | $1.34B | 0.35% |
DFSV | 36.01% | $4.53B | 0.3% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
VIXY | -23.10% | $196.95M | 0.85% |
TAIL | -22.50% | $104.04M | 0.59% |
FXY | -20.55% | $859.86M | 0.4% |
IVOL | -14.46% | $346.82M | 1.02% |
SHYM | -14.09% | $324.29M | 0.35% |
JMST | -13.46% | $3.97B | 0.18% |
BSMW | -13.02% | $104.76M | 0.18% |
FTSD | -12.13% | $228.45M | 0.25% |
BTAL | -11.62% | $296.94M | 1.43% |
PHDG | -9.97% | $92.15M | 0.39% |
MEAR | -9.78% | $1.09B | 0.25% |
CGSM | -9.51% | $690.81M | 0.25% |
CTA | -9.21% | $1.09B | 0.76% |
IBTI | -8.97% | $1.04B | 0.07% |
IBTL | -8.84% | $374.78M | 0.07% |
IBTH | -8.62% | $1.58B | 0.07% |
MUST | -8.60% | $431.92M | 0.23% |
IBTK | -8.50% | $433.66M | 0.07% |
SCHO | -8.27% | $10.94B | 0.03% |
IAGG | -7.64% | $10.35B | 0.07% |
Current Value
$32.281 Year Return
Current Value
$32.281 Year Return